Korea Research Institute of Bioscience and Biotechnology

Industry-University Cooperation Foundation Hanyang University

Postech Academy-Industry Foundation

Konkuk University Industrial Cooperation Corp

Korea University Industrial Academic Collaboration Foundation

Engene, Inc.

Korea University Industry and Academy Collaboration Foundation

Kr Biotech Co., Ltd.

Yu-Kyoung Oh

Young Ho Kim

Chae Ok Yun

Young Il Yeom

Hee Gu Lee

Kyung-Sook Chung

Eun Young Song

Young Joo Kim

Moon Hee Kim

Kyeong-Eun Jung

Misun Won

Kyung Bin Song

Hye Kyung Hong

Hee Jung Lee

Myung Suk Kim

Myung-Ok Park

Nuri Park

Hyun-Gu Kang

Sang Myoung Noh

Sei-Kwang Hahn

Jong Oh Kim

Young-Bong Kim

Sung Sik Bang

Ji-Seok Kim

Han-Gon Choi

Dong Wuk Kim

Jiang Ge

Ki-Su Kim

Ki-Tae Park

Dong Shik Kim

Su-Eun Han

Ga-Yong Shim

Ii-Hwan Cho

Fakhar Ud Din

Chul Soon Yong

Ga Yong Shim

Sang-Hee Kim

Provided is an irinotecan-loaded dual-reverse thermosensitive formulation, which is a dual-reverse thermosensitive hydrogel composition including nanoparticles including irinotecan and lipids; a hydrogel; and a stabilizer.

Irinotecan-loaded dual-reverse thermosensitive hydrogel composition

The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.

Baculovirus-based vaccines

The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.

Pharmaceutical composition for treating cancer

The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.

Chitosan based polymer conjugate and a method for producing the same

The present invention relates to a delivery system for nucleic acid using a cationic polymer conjugate, and more specifically relates to a delivery system for nucleic acid comprising a cationic polymer conjugate prepared by conjugating hyaluronic acid or its derivative and polyethyleneimine, and a composition of delivering a nucleic acid into mammalian cell comprising a complex of the nucleic acid and a cationic polymer conjugate with electrostatic binding.

Nucleic acid delivery system comprising conjugates of PEI and hyaluronic acid

The present invention provides a small interfering RNA (siRNA) that is capable of inhibiting intracellular expression of Wnt1 through complementary binding to a Wnt1 transcript (mRNA transcript) base sequence and a pharmaceutical composition for treating cancer comprising the same. siRNA of the present invention which is complementary to a base sequence of a Wnt1 transcript (mRNA) provides apoptotic cancer cell death due to inhibition of expression of Wnt1 commonly expressed in cancer cells, by RNA-mediated interference (RNAi). Therefore, the composition of the present invention comprising the same can be used as an excellent anticancer drug.

Growing community of inventors

Seoul, South Korea

Yu-Kyoung Oh